Peripheral Blood Stem Cells
Peripheral Blood Stem Cells - Related Videos
09:45
Generation of Integration-free Induced Pluripotent Stem Cells from Human Peripheral Blood Mononuclear Cells Using Episomal Vectors
0 Views •
Cited by 17 •
2017
This protocol describes a detailed method for efficient generation of integration-free iPSCs from human adult peripheral blood cells. With the use of four oriP/EBNA-based episomal vectors to express the reprogramming factors, KLF4, MYC, BCL-XL, or OCT4 and SOX2, thousands of iPSC colonies can be obtained from 1 mL of peripheral blood.
12:06
Direct Induction of Human Neural Stem Cells from Peripheral Blood Hematopoietic Progenitor Cells
0 Views •
Cited by 15 •
2015
A method was developed to directly derive human neural stem cells from hematopoietic progenitor cells enriched from peripheral blood cells.
12:03
Generation of Human Induced Pluripotent Stem Cells from Peripheral Blood Using the STEMCCA Lentiviral Vector
0 Views •
Cited by 80 •
2012
Here we show a simple and effective protocol for the generation of human iPSCs from 3-4 ml of peripheral blood using a single lentiviral reprogramming vector. Reprogramming of readily available blood cells promises to accelerate the utilization of iPSC technology by making it accessible to a broader research community.
07:51
Differentiating Chondrocytes from Peripheral Blood-derived Human Induced Pluripotent Stem Cells
0 Views •
Cited by 6 •
2017
We present a protocol to generate a chondrogenic lineage from human peripheral blood (PB) via induced pluripotent stem cells (iPSCs) using an integration-free method, which includes embryoid body (EB) formation, fibroblastic cells expansion, and chondrogenic induction.
11:00
Generation and Culture of Blood Outgrowth Endothelial Cells from Human Peripheral Blood
0 Views •
Cited by 74 •
2015
This protocol allows for the reliable generation and characterization of blood outgrowth endothelial cells (BOECs) from a small volume of adult peripheral blood. BOECs can be used as a surrogate for endothelial cells from patients with vascular disorders and as a substrate for the generation of induced pluripotent stem cells.
FAQs
Granulocyte colony-stimulating factor, or G-CSF, changes the location of blood-forming stem cells rather than creating a new cell population. It mobilizes cells that normally remain mainly in bone marrow into the bloodstream. This increase in circulating cells makes it possible to obtain a stem-cell-rich fraction through leukapheresis for later transplantation.
Leukapheresis provides the collection step after stem cells have entered the circulation. The procedure separates blood components and captures the fraction enriched in blood-forming stem cells. This collected product can then be prepared for transplantation, including preservation when it will not be infused immediately after collection.
After infusion, the collected cells migrate to the bone marrow, where they support regeneration of blood and immune cells. This restorative capacity is important after treatment has substantially affected marrow function. Successful repopulation helps reestablish the systems needed for blood production and immune recovery following intensive therapy.
Conditioning with chemotherapy or radiation creates the treatment context in which the collected stem cells are infused to restore marrow function. The approach is used after intensive therapy, when blood-forming capacity requires reconstitution. Infusion of the prepared cells therefore serves as a recovery strategy following marrow-disrupting treatment.
The workflow begins with medication-assisted mobilization, followed by leukapheresis to collect the stem-cell-rich blood fraction. The product may be cryopreserved, meaning stored at very low temperature, until needed. The patient then receives chemotherapy or radiation conditioning, and the collected cells are infused to support marrow regeneration.
This approach supports autologous and allogeneic transplantation for several serious disorders. The listed applications include leukemia, lymphoma, and multiple myeloma, along with selected nonmalignant diseases. Its clinical value comes from restoring blood and immune cell production after intensive treatment has impaired normal bone marrow function.
Peripheral blood stem cells can serve in both autologous and allogeneic transplantation settings. The source material identifies these as two clinical uses rather than limiting the method to one transplant approach. Consequently, the same collection and infusion strategy can contribute to treatment plans for malignant disorders and selected nonmalignant diseases.